Tykerb (Lapatinib Ditosylate) Patent Expiration, LOE Window & CMS Spending

Tykerb (Lapatinib Ditosylate) by Novartis: FDA Orange Book core substance LOE 2029-09-18, 2 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022059 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-09-18
Last Listed Patent or Exclusivity Date2029-09-18
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$2.7M
2024 Medicaid Spend$601K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.